Clinical trials: Neoplastic Processes
Gastrointestinal Stromal Tumors
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
- Trial name
- NCT00812240
- Testing
- Masitinib, Imatinib
- Where
- 41 sites in United States, France and 1 more
- Volunteers
- 335 people
- Sponsor
- AB Science
Gastric Cancers
Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer
This study aims to explore lymph node metastasis in the short gastric mesentery following total gastrectomy with D2 lymphadenectomy plus complete mesogastric excision, providing evidence-based medicine for standardizing lymph…
- Trial name
- zytg001 (NCT06728878)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jichao Qin
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first…
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT04514497
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 23 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasms, Liver Neoplasms
Colorectal Cancer With Liver-limited Synchronous Metastases: an Inception Cohort Study of Standardised Care Pathways
Background When first diagnosed, colorectal cancer has already metastasized in about 20% of patients to the liver or further (termed synchronous disease).
- Conditions
- Colorectal Neoplasms, Liver Neoplasms, Neoplasm Metastasis
- Trial name
- CoSMIC (NCT02456285)
- Testing
- Primary/Bowel-first Surgery, Liver-first surgery, Synchronous resection surgery
- Where
- United Kingdom
- Volunteers
- 123 people
- Sponsor
- Manchester University NHS Foundation Trust
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00544115
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Volunteers
- 260 people
- Sponsor
- City of Hope Medical Center
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00816413
- Testing
- cyclosporine, mycophenolate mofetil, pentostatin
- Sponsor
- University of Nebraska
Malignant Solid Tumor, Metastatic Cancer
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
This is a phase 1 open-label trial to evaluate the safety, pharmacodynamics and clinical activity of RRx-001 administered in combination with irinotecan.
- Conditions
- Malignant Solid Tumor, Metastatic Cancer, Advanced Cancer
- Trial name
- PAYLOAD (NCT02801097)
- Testing
- RRx-001, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- EpicentRx, Inc.
Head and Neck Squamous Cell Carcinoma, Lymph Node Metastasis
Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
This study evaluates the safety and effectiveness of MPB-2043, a superparamagnetic iron oxide (SPIO) contrast agent, for enhancing MRI in detecting metastatic lymph nodes in head and neck cancer.
- Trial name
- NCT06540443
- Testing
- MPB-2043 of 0.5 mg/kg, MPB-2043 of 1.0 mg/kg, MPB-2043 of 2.0 mg/kg
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- MegaPro Biomedical Co. Ltd.
Advance Solid Tumors
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT07229313
- Testing
- KIVU-107
- Where
- 7 sites in United States, Australia
- Volunteers
- 76 people
- Sponsor
- Kivu Bioscience Inc.
Advanced Cancer, Metastatic Cancer
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART0380 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04657068
- Testing
- ART0380, Gemcitabine, Irinotecan
- Where
- 88 sites in United States, France and 2 more
- Volunteers
- 542 people
- Sponsor
- Artios Pharma Ltd
Oncology, Tumor Recurrence and Metastasis
Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorectal Cancer
The main objective of this study was to evaluate the effect of surgical margin width on the prognosis of patients with hepatic oligometastasis of colorectal cancer by statistical 1-year intrahepatic recurrence-free survival rate…
- Trial name
- NCT06934018
- Testing
- Surgery and procedure
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fudan University
Breast Cancer, Metastatic Cancer
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
This study is a prospective, single-center, open-label, umbrella-shaped phase II clinical study for patients with HR+/HER2- endocrine-resistant advanced breast cancer.
- Trial name
- MULAN (NCT04355858)
- Testing
- SHR7390, Famitinib, SHR3162
- Where
- China
- Volunteers
- 319 people
- Sponsor
- Fudan University
Melanoma
Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
This study will investigate the combination of two drugs, trametinib and nab-paclitaxel, in patients with advanced unresectable or metastatic melanoma. Each drug has shown activity in trials of patients with melanoma.
- Trial name
- NCT02300935
- Testing
- trametinib, nab-paclitaxel
- Where
- 3 sites in United States
- Sponsor
- SCRI Development Innovations, LLC
Locally Advanced Pancreatic Cancer
Metastatic Advanced Pancreas Sorafenib
This is multicentre, open-label, randomized, phase II trial in patients with locally advanced or metastatic pancreatic cancer. Subjects will be randomized in a 1:1 ratio to receive gemcitabine/cisplatin in combination with…
- Trial name
- MAPS (NCT00758381)
- Testing
- Sorafenib 400 mg po bid, continuously, Gemcitabina, Cisplatino
- Where
- 17 sites in Italy
- Volunteers
- 114 people
- Sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Myeloma
Non-invasive MRD Assessment in Multiple Myeloma
The purpose of this study is to investigate the sensitivity and accuracy of non-invasive MRD assessment using liquid biopsy (blood draw) and functional imaging (whole body MRI) in participants with new diagnosed and previously…
- Trial name
- NIRVANA (NCT05625971)
- Testing
- MRD Assessment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Rajshekhar Chakraborty, MD
Neoplasms, Unknown Primary
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
This trial will investigate the combination of bevacizumab, and erlotinib in patients with adenocarcinoma or poorly differentiated carcinoma of unknown primary site.
- Trial name
- NCT00193622
- Testing
- Bevacizumab, Erlotinib
- Volunteers
- 50 people
- Sponsor
- SCRI Development Innovations, LLC
Melanoma, Metastatic Melanoma
Phase II Trial of Allovectin-7® for Metastatic Melanoma
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.
- Conditions
- Melanoma, Metastatic Melanoma, Malignant Melanoma, Skin Cancer
- Trial name
- NCT00044356
- Testing
- Allovectin-7®
- Where
- 16 sites in United States
- Volunteers
- 133 people
- Sponsor
- Vical
Acute Lymphoblastic Leukemia, Complete Hematologic Remission (CHR)
Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)
The present study aims at studying how safe and tolerable a new therapy for patients with Acute Lymphoblastic Leukemia (ALL) is.
- Conditions
- Acute Lymphoblastic Leukemia, Complete Hematologic Remission (CHR), Persistent/Recurrent Minimal Residual Disease (MRD)
- Trial name
- NCT02185781
- Testing
- Autologous NK cells infusions
- Where
- 6 sites in Italy
- Volunteers
- 6 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Breast Cancer, Prostate Cancer
Collection of Blood Specimens for Circulating Tumor Cell Analysis
Objective: To test the sensitivity of a proprietary novel filtration device designed to capture and concentrate circulating tumor cells (CTCs).
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT01943500
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Viatar LLC
Non Small Cell Lung Cancer, EGFR Gene Mutation
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The primary objective of the study is to evaluate the efficacy of osimertinib plus ramucirumab versus osimertinib alone using progression free survival (PFS).
- Conditions
- Non Small Cell Lung Cancer, EGFR Gene Mutation, Advanced Cancer, Metastatic Cancer
- Trial name
- NCT03909334
- Testing
- Osimertinib, Ramucirumab
- Where
- 12 sites in United States
- Volunteers
- 160 people
- Sponsor
- Xiuning Le